Ocular Toxicity in GD-2 Antibody Therapy: A Case Study.

Area of Science:

• Pediatric Oncology
• Ophthalmology
• Pharmacology

Background:

• Neuroblastoma treatment with GD-2 antibodies, such as dinutuximab, can rarely cause ocular toxicities.
• Ocular adverse events, including pupillary palsy, visual acuity changes, and photophobia, require careful monitoring.

Purpose of the Study:

• To present the clinical presentation and management of two cases of ocular toxicity in children undergoing dinutuximab therapy.
• To emphasize the importance of healthcare providers in recognizing and reporting ocular adverse effects.

Main Methods:

• A case study of a 6-year-old boy with high-risk neuroblastoma treated with dinutuximab.
• Ophthalmological evaluation and symptomatic treatment with pilocarpine drops and sunglasses.

Main Results:

• The patient experienced bilateral mydriasis, decreased visual acuity, and photophobia after dinutuximab therapy.
• Pilocarpine provided some relief from photophobia and improved pupillary response, though visual acuity did not fully recover.
• Lack of baseline visual screening hindered precise toxicity assessment, and treatment was continued due to greater risks associated with dose modification.

Conclusions:

• Baseline ophthalmological screening is essential before initiating GD-2 antibody therapy to accurately assess visual changes.
• Less common ocular toxicities associated with dinutuximab therapy may be underreported, necessitating improved recognition and management strategies for healthcare providers.